I am asking mechanistically rather than practically — I want the model, not the protocol.
The comparison I want does not seem to exist anywhere in a form I can evaluate.
I have read the arguments for each and they do not engage with each other.
So which one, and on what grounds?
The honest answer is that the combination works, that the margin over semaglutide alone is real, and that it was smaller than the phase 2 signal suggested.
REDEFINE-1 reported mean weight reduction around twenty-two to twenty-three per cent at 68 weeks in adults with obesity and without diabetes, against roughly sixteen per cent for semaglutide alone and about eleven for cagrilintide alone in the same trial.
The amylin receptor is the calcitonin receptor in complex with a receptor-activity-modifying protein, so the pharmacology is genuinely distinct from anything in the incretin class.
The REDEFINE programme is the appropriate citation for combination results, with REDEFINE-1 in obesity without diabetes and further trials in other populations.
The caveat is that a fixed combination has a tolerability profile of its own that cannot be inferred by adding the components.
Both components hit the area postrema, which is why titration is careful.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs the comparator, because the interesting question is not whether it beats placebo but by how much it beats each component alone.
Cagrilintide is an acylated long-acting amylin analogue designed for weekly administration; semaglutide is the GLP-1 agonist component. The receptors are unrelated, which is the basis for additivity.
The underlying point is that the glycaemic component in the diabetes population behaves differently from the weight component, and the two trials in the programme should be read separately.
Pramlintide, the older amylin analogue, provides the long-term clinical experience with amylin agonism, at a very different dosing frequency.
Fixed combination means fixed ratio. That is a real constraint.
The relevant point is that this is a fixed-dose combination, so the two components titrate together and cannot be adjusted independently.
Both components act at the area postrema, so the gastrointestinal tolerability profile is not simply the sum of the two and the titration schedule reflects that.
In practice, a fixed combination removes the ability to titrate one component against the other, which simplifies administration and constrains individualisation.
The amylin receptor architecture — calcitonin receptor plus RAMP — is established pharmacology and explains why selectivity was hard.
Nothing here is medical advice.
The expectation gap is a story about expectations, not about the pharmacology.
edited 26 Mar 2025 by lyoph_cake — clarified the distinction between purity and content
Stated carefully, tolerability of the combination is the practical question, since both components act at the same brainstem region.
The pre-trial expectation in some quarters had drifted towards twenty-five per cent, so a result above every comparator was received as a shortfall. That is a lesson about expectations rather than about the compound.
Read REDEFINE against the monotherapy arms, not against placebo.
Answer first: a fixed combination of cagrilintide, a long-acting amylin analogue, with semaglutide — two mechanisms, two receptors, one weekly injection.
For research-grade material, a combination is two identity problems and two content problems rather than one, and there is no reason to expect a supplier to have solved either.
Cagrilintide monotherapy phase 2 results establish the component effect and are what the combination arm should be read against.
A trial result below an informal expectation is not a failed trial, and the two get conflated in summaries.
Two mechanisms, two receptors, one injection. That is the design.
edited 8 Feb 2025 by harriet_lonsdale — corrected a unit error in the worked example
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.